United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

martindale pharmaceuticals ltd - pilocarpine hydrochloride - eye drops - 10mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

martindale pharmaceuticals ltd - pilocarpine hydrochloride - eye drops - 20mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

martindale pharmaceuticals ltd - pilocarpine hydrochloride - eye drops - 40mg/1ml

Malta - English - Medicines Authority

macarthys laboratories limited bampton road, harold hill, romford essex, rm3 8ug, united kingdom - pilocarpine hydrochloride - eye drops - pilocarpine hydrochloride 20 mg/ml - ophthalmologicals

Malta - English - Medicines Authority

macarthys laboratories limited bampton road, harold hill, romford essex, rm3 8ug, united kingdom - pilocarpine hydrochloride - eye drops - pilocarpine hydrochloride 1 % (w/v) - ophthalmologicals

Malta - English - Medicines Authority

macarthys laboratories limited bampton road, harold hill, romford essex, rm3 8ug, united kingdom - pilocarpine hydrochloride - eye drops - pilocarpine hydrochloride 4 % (w/v) - ophthalmologicals

Ireland - English - HPRA (Health Products Regulatory Authority)

martindale pharmaceuticals ltd - pilocarpine hydrochloride - eye drops, solution - 2 percent weight/volume - parasympathomimetics; pilocarpine

Ireland - English - HPRA (Health Products Regulatory Authority)

martindale pharmaceuticals ltd - pilocarpine hydrochloride - eye drops, solution - 4 percent weight/volume - parasympathomimetics; pilocarpine

United States - English - NLM (National Library of Medicine)

general injectables and vaccines, inc - neostigmine methylsulfate (unii: 98imh7m386) (neostigmine - unii:3982twq96g) - neostigmine methylsulfate 1 mg in 1 ml - neostigmine methylsulfate injection, a cholinesterase inhibitor, is indicated for reversal of the effects of nondepolarizing neuromuscular blocking agents (nmba) after surgery.  neostigmine is contraindicated in patients with: - known hypersensitivity to neostigmine methylsulfate (known hypersensitivity reactions have included urticaria, angioedema, erythema multiforme, generalized rash, facial swelling, peripheral edema, pyrexia, flushing, hypotension, bronchospasm, bradycardia and anaphylaxis).  - peritonitis or mechanical obstruction of the urinary or intestinal tracts. pregnancy risk summary there are no adequate or well-controlled studies of neostigmine methylsulfate injection in pregnant women.  it is not known whether neostigmine methylsulfate injection can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity.  the incidence of malformations in human pregnancies has not been established for neostigmine as the data are limited.  all pregnancies, regardless of drug e

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - neostigmine methylsulfate (unii: 98imh7m386) (neostigmine - unii:3982twq96g) - neostigmine methylsulfate 0.5 mg in 1 ml - neostigmine methylsulfate injection, a cholinesterase inhibitor, is indicated for reversal of the effects of nondepolarizing neuromuscular blocking agents (nmba) after surgery.  neostigmine is contraindicated in patients with: - known hypersensitivity to neostigmine methylsulfate (known hypersensitivity reactions have included urticaria, angioedema, erythema multiforme, generalized rash, facial swelling, peripheral edema, pyrexia, flushing, hypotension, bronchospasm, bradycardia and anaphylaxis).  - peritonitis or mechanical obstruction of the urinary or intestinal tracts. risk summary there are no adequate or well-controlled studies of neostigmine methylsulfate injection in pregnant women.  it is not known whether neostigmine methylsulfate injection can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity.  the incidence of malformations in human pregnancies has not been established for neostigmine as the data are limited.  all pregnancies, regardless of drug exposure, h